A Benefit-Risk Assessment of Extended-Release Oxybutynin

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.12, 2002-01, pp. : 867-876

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extended-Release Oxybutynin

By Comer A.M. Goa K.L.

Drugs & Aging, Vol. 16, Iss. 2, 2000-02 ,pp. : 149-155

Adis International

Access to resources Recommend Favorite

Extended-release oxybutynin an effective option in overactive bladder

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite

Extended-Release Oxybutynin: A Viewpoint by Rodney U. Anderson

By Leach G.E.

Drugs & Aging, Vol. 16, Iss. 2, 2000-02 ,pp. : 156-157

Adis International

Access to resources Recommend Favorite

Effect of Antacid on the Pharmacokinetics of Extended-Release Formulations of Tolterodine and Oxybutynin

By Gayatri Sathyan

Clinical Pharmacokinetics, Vol. 43, Iss. 14, 2004-01 ,pp. : 1059-1068

Adis International

Access to resources Recommend Favorite

Oxybutynin Extended-Release: A Review of its Use in the Management of Overactive Bladder

By Siddiqui M.A.A. Perry C.M. Scott L.J.

Drugs, Vol. 64, Iss. 8, 2004-01 ,pp. : 885-912

Adis International

Access to resources Recommend Favorite